Clostridium difficile isolates resistant to fluoroquinolones in Italy: Emergence of PCR ribotype 018

Journal of Clinical Microbiology

Volumn 48, Issue 8, 2010, Pages 2892-2896

  Spigaglia, Patrizia ^a   Barbanti, Fabrizio ^a   Dionisi, Anna Maria ^a   Mastrantonio, Paola ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LINCOSAMIDE; MIKAMYCIN B; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; THREONINE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); MACROLIDE; QUINOLONE DERIVATIVE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; CLOSTRIDIUM DIFFICILE; ERM GENE; GENE MUTATION; GYR GENE; ISOLATION PROCEDURE; ITALY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; BACTERIUM IDENTIFICATION; CLASSIFICATION; DRUG EFFECTS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULAR EPIDEMIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; PROCEDURES; RIBOTYPING;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BACTERIAL TYPING TECHNIQUES; CLOSTRIDIUM DIFFICILE; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FLUOROQUINOLONES; HUMANS; ITALY; LINCOSAMIDES; MACROLIDES; MICROBIAL SENSITIVITY TESTS; MOLECULAR EPIDEMIOLOGY; POLYMERASE CHAIN REACTION; RIBOTYPING; STREPTOGRAMIN B;

CLOSTRIDIUM DIFFICILE;

EID: 77955433596     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02482-09     Document Type: Article

References (39)

1. Ackermann, G., A. Degner, H. Cohen, J. Silva, Jr., and A. C. Rodloff. 2003. Prevalence and association of macrolide-lincosamide-streptogramin B (MLSB) resistance with resistance to moxifloxacin in Clostridium difficile. J. Antimicrob. Chemother. 51:599-603.
2. Barbut, F., P. Mastrantonio, M. Delmee, J. Brazier, E. Kuijper, and I. Poxton. 2007. Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. European Study Group on Clostridium difficile. Clin. Microbiol. Infect. 13:1048-1057. (Pubitemid 47553515)
3. Bartlett, J. G. 2002. Clostridium difficile-associated enteric disease. Curr. Infect. Dis. Rep. 4:477-483.
4. Bartlett, J. G. 2006. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann. Intern. Med. 145:758-764.
5. Bidet, P., F. Barbut, V. Lalande, B. Burghoffer, and J. C. Petit. 1999. Development of a new PCR-ribotyping method for Clostridium difficile based on ribosomal RNA gene sequencing. FEMS Microbiol. Lett. 175:261-266.
6. Biller, P., B. Shank, L. Lind, M. Brennan, L. Tkatch, G. Killgore, A. Thompson, and L. C. McDonald. 2007. Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain. Infect. Control Hosp. Epidemiol. 28:198-201.
7. Blondeau, J. M. 2009. What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhoea? J. Antimicrob. Chemother. 63:238-242.
8. Clinical and Laboratory Standards Institute. 2007. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 7th ed. Approved standard M11-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Coia, J. E. 2009. What is the role of antimicrobial resistance in the new epidemic of Clostridium difficile? Int. J. Antimicrob. Agents 33(Suppl. 1):S9-S12.
10. Debast, S. B., L. A. van Leengoed, A. Goorhuis, C. Harmanus, E. J. Kuijper, and A. A. Bergwerff. 2009. Clostridium difficile PCR ribotype 078 toxinotype V found in diarrhoeal pigs identical to isolates from affected humans. Environ. Microbiol. 11:505-511.
11. Dridi, L., J. Tankovic, B. Burghoffer, F. Barbut, and J. C. Petit. 2002. gyrA and gyrB mutations are implicated in cross-resistance to ciprofloxacin and moxifloxacin in Clostridium difficile. Antimicrob. Agents Chemother. 46: 3418-3421. (Pubitemid 35192906)
12. Drudy, D., L. Kyne, R. O'Mahony, and S. Fanning. 2007. gyrA mutations in fluoroquinolone-resistant Clostridium difficile PCR-027. Emerg. Infect. Dis. 13:504-505.
13. Hooper, D. C. 2001. Emerging mechanisms of fluoroquinolone resistance. Emerg. Infect. Dis. 7:337-344.
14. Huang, H., S. Wu, M. Wang, Y. Zhang, H. Fang, A. C. Palmgren, A. Weintraub, and C. E. Nord. 2009. Clostridium difficile infections in a Shanghai hospital: antimicrobial resistance, toxin profiles and ribotypes. Int. J. Antimicrob. Agents 33:339-342.
15. Johnson, S., M. H. Samore, K. A. Farrow, G. E. Killgore, F. C. Tenover, D. Lyras, J. I. Rood, P. DeGirolami, A. L. Baltch, M. E. Rafferty, S. M. Pear, and D. N. Gerding. 1999. Epidemics of diarrhea caused by a clindamycinresistant strain of Clostridium difficile in four hospitals. N. Engl. J. Med. 341:1645-1651.
16. Kato, H., Y. Ito, R. van den Berg, E. J. Kuijper, and Y. Arakawa. 2007. First isolation of Clostridium difficile 027 in Japan. Euro Surveill. 12:E070111.3. http://www.eurosurveillance.org/ew/2007/070111.asp#3.
17. Keel, K., J. S. Brazier, K. W. Post, S. Weese, and J. G. Songer. 2007. Prevalence of PCR ribotypes among Clostridium difficile isolates from pigs, calves, and other species. J. Clin. Microbiol. 45:1963-1964.
18. Kuijper, E. J., B. Coignard, and P. Tüll. 2006. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin. Microbiol. Infect. 12(Suppl. 6):2-18.
19. Kuijper, E. J., R. J. van den Berg, S. Debast, C. E. Visser, D. Veenendaal, A. Troelstra, T. van der Kooi, S. van den Hof, S. and D. W. Notermans. 2006. Clostridium difficile ribotype 027, toxinotype III, the Netherlands. Emerg. Infect. Dis. 12:827-830.
20. Kuijper, E. J., B. Coignard, J. Brazier, C. Suetens, D. Drudy, C. Wiuff, H. Pituch, P. Reichert, F. Schneider, A. F. Widmer, K. E. Olsen, F. Allerberger, D. W. Notermans, F. Barbut, M. Delmée, M. Wilcox, P. Pearson, B. Patel, D. J. Brown, R. Frei, T. Akerlund, I. R. Poxton, and P. Tüll. 2007. Update of Clostridium difficile-associated disease due to PCR ribotype 027 in Europe. Euro Surveill. 12:714. http://www.eurosurveillance.org/em/v12n06/1206-221.asp.
21. Labbé, A. C., L. Poirier, D. MacCannell, T. Louie, M. Savoie, C. Béliveau, M. Laverdière, and J. Pépin. 2008. Clostridium difficile infections (CDI) in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. Antimicrob. Agents Chemother. 52: 3180-3187.
22. Loo, V. G., L. Poirier, M. A. Miller, M. Oughton, M. D. Libman, S. Michaud, A. M. Bourgault, T. Nguyen, C. Frenette, M. Kelly, A. Vibien, P. Brassard, S. Fenn, K. Dewar, T. J. Hudson, R. Horn, P. René, Y. Monczak, and A. Dascal. 2005. A predominantly clonal multiinstitutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 353:2442-2449.
23. Mutlu, E., A. J. Wroe, K. Sanchez-Hurtado, J. S. Brazier, and I. R. Poxton. 2007. Molecular characterization and antimicrobial susceptibility patterns of Clostridium difficile strains isolated from hospitals in south-east Scotland. J. Med. Microbiol. 56:921-929.
24. Muto, C. A., M. Pokrywka, K. Shutt, A. B. Mendelsohn, K. Nouri, K. Posey, T. Roberts, K. Croyle, S. Krystofiak, S. Patel-Brown, A. W. Pasculle, D. L. Paterson, M. Saul, and L. H. Harrison. 2005. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect. Control Hosp. Epidemiol. 26:273-280.
25. Owens R. C., Jr., C. J. Donskey, R. P. Gaynes, V. G. Loo, and C. A. Muto. 2008. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin. Infect. Dis. 15(Suppl. 1):S19-S31.
26. Pepin, J., N. Saheb, M. A. Coulombe, M. F. Alary, M. P. Corriveau, S. Authier, M. Leblanc, G. Rivard, M. Bettez, V. Primeau, M. Nguyen, C. E. Jacob, and L. Lanthier. 2005. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin. Infect. Dis. 41:1254-1260.
27. Piddock, L. J. 1999. Mechanisms of fluoroquinolone resistance: an update, 1994-1998. Drugs 58(Suppl. 2):11-18.
28. Pituch, H., J. S. Brazier, P. Obuch-Woszczatynski, D. Wultanska, F. Meisel- Mikolajczyk, and M. Luczak. 2006. Prevalence and association of PCR ribotypes of Clostridium difficile isolated from symptomatic patients from Warsaw with macrolide-lincosamide-streptogramin B (MLSB) type resistance. J. Med. Microbiol. 55:207-213.
29. Ruiz, J. 2003. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J. Antimicrob. Chemother. 51:1109-1117.
30. Rupnik, M., M. H. Wilcox, and D. N. Gerding. 2009. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat. Rev. Microbiol. 7:526-536.
31. Russo, P. 2009. Uso dei farmaci antibiotici in Italia e in Europa, p. 15-17. In A. Pantosti and M. Del Grosso (ed.), Giornata europea degli antibiotici: uso responsabile per il controllo dell'antibiotico-resistenza. Rapporti ISTISAN 09/32. Istituto Superiore di Sanità, Rome, Italy.
32. Spigaglia, P., and P. Mastrantonio. 2004. Comparative analysis of Clostridium difficile clinical isolates belonging to different genetic lineages and time periods. J. Med. Microbiol. 53:1129-1136.
33. Spigaglia, P., V. Carucci, F. Barbanti, and P. Mastrantonio. 2005. ErmB determinants and Tn916-like elements from clinical isolates of Clostridium difficile. Antimicrob. Agents Chemother. 49:2550-2553.
34. Spigaglia, P., F. Barbanti, P. Mastrantonio, J. S. Brazier, F. Barbut, M. Delmée, E. Kuijper, and I. R. Poxton. 2008. Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe. European Study Group on Clostridium difficile. J. Med. Microbiol. 57:784-789. (Pubitemid 351842073)
35. Spigaglia, P., A. Carattoli, F. Barbanti, and P. Mastrantonio. 21 October 2009, posting date. Detection of gyrA and gyrB mutations in Clostridium difficile isolates by real-time PCR. Mol. Cell Probes [Epub ahead of print.] doi:10.1016/j.mcp. 2009.10.002.
36. Stubbs, S., M. Rupnik, M. Gibert, J. Brazier, B. Duerden, and M. Popoff. 2000. Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol. Lett. 186:307-312.
37. Terhes, G., J. S. Brazier, E. Urbán, J. Sóki, and E. Nagy. 2006. Distribution of Clostridium difficile PCR ribotypes in regions of Hungary. J. Med. Microbiol. 55:279-282.
38. Vaccheri, A., M. C. Silvani, L. Bersaglia, D. Motola, P. Strahinja, A. Vargiu, E. Poluzzi, and N. Montanaro. 2008. A 3 year survey on the use of antibacterial agents in five Italian hospitals. J. Antimicrob. Chemother. 61:953-958.
39. Wilcox, M. H. 2003. Gastrointestinal disorders and the critically ill. Clostridium difficile infection and pseudomembranous colitis. Best Pract. Res. Clin. Gastroenterol. 17:475-493.